Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

NCT02603809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1659

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Aprocitentan 5 mg
DRUG: Aprocitentan 10 mg
DRUG: Aprocitentan 25 mg
DRUG: Aprocitentan 50 mg
DRUG: Lisinopril 20 mg
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.